CoChat

Passiflora for anxiety disorder

Miyasaka, Lincoln Sakiara, Atallah, Álvaro N, Soares, Bernardo · 2007 · Cochrane Database of Systematic Reviews
Cited by 78

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Anxiety is a very common mental health problem in the general population and in the primary care setting. Herbal medicines are popularly used worldwide and could be an option for treating anxiety if shown to be effective and safe. Passiflora (passionflower extract) is one of these compounds. OBJECTIVES: To investigate the effectiveness and safety of passiflora for treating any anxiety disorder. SEARCH STRATEGY: The following sources were used: electronic databases: Cochrane Collaboration Depression, Anxiety and Neurosis Cochrane Controlled Trials Register (CCDANCTR-Studies), Medline and Lilacs; Cross-checking references; contact with authors of included studies and manufacturers of passiflora. SELECTION CRITERIA: Relevant randomised and quasi-randomised controlled trials of passiflora using any dose, regime, or method of administration for people with any primary diagnosis of general anxiety disorder, anxiety neurosis, chronic anxiety status or any other mental health disorder in which anxiety is a core symptom (panic disorder, obsessive compulsive disorder, social phobia, agoraphobia, other types of phobia, postraumatic stress disorder). Effectiveness was measured using clinical outcome measures such as Hamilton Anxiety Scale (HAM-A) and other scales for anxiety symptoms. DATA COLLECTION AND ANALYSIS: Two reviewers independently selected the trials found through the search strategy, extracted data, performed the trial quality analyses and entered data. Where any disagreements occured, the third reviewer was consulted. Methodological quality of the trials included in this review was assessed using the criteria described in the Cochrane Handbook. For dichotomous outcomes, relative risk with 95% confidence intervals (CI) were calculated, and for continuous outcomes, weighted mean difference with 95%CI was used. MAIN RESULTS: Two studies, with a total of 198 participants, were eligible for inclusion in this review. Based on one study, a lack of difference in the efficacy of benzodiazepines and passiflora was indicated. Dropout rates were similar between the two interventions. Although the findings from one study suggested an improvement in job performance in favour of passiflora (post-hoc outcome) and one study showed a lower rate of drowsiness as a side effect with passiflora as compared with mexazolam, neither of these findings reached statistical significance. AUTHORS' CONCLUSIONS: RCTs examining the effectiveness of passiflora for anxiety are too few in number to permit any conclusions to be drawn. RCTs with larger samples that compare the effectiveness of passiflora with placebo and other types of medication, including antidepressants, are needed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd004518.pub2

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 20

  1. Akhondzadeh, 2001, Passionflower in the treatment of generalized anxiety: a pilot double-blind randomized controlled trial with oxazepam, Journal of Clinical Pharmacy and Therapeutics, 26, 363, 10.1046/j.1365-2710.2001.00367.x · DOI · Paper page
  2. Mori, 1993, Clinical Evaluation of Passiflamin (passiflora extract) on neurosis - multicenter double blind study in comparison with mexazolam, Clinical Evaluation, 21, 383
  3. Bourin, 1997, A combination of plant extracts in the treatment of outpatients with adjustment disorder with anxious mood: controlled study versus placebo, Fundamental & Clinical Pharmacology, 11, 127, 10.1111/j.1472-8206.1997.tb00179.x · DOI · Paper page
  4. Almeida-Filho, 1997, Brazilian multicentric study of psychiatric morbidity. Methodological features and prevalence estimates, British Journal of Psychiatry, 171, 524, 10.1192/bjp.171.6.524 · DOI · Paper page
  5. Borkovec, 1987, The effects of relaxation training with cognitive or nondirective therapy and the role of relaxation-induced anxiety in the treatment of generalized anxiety disorder, Journal of Consulting & Clinical Psychology, 55, 883, 10.1037/0022-006X.55.6.883 · DOI
  6. Clarke, 2000, Cochrane Collaboration Handbook
  7. Fisher, 2000, Toxicity of Passiflora incarnata, Clinical Toxicology, 38, 63, 10.3109/15563650.2013.870343 · doi:10.3109/15563650.2013.870343
  8. Hamilton, 1959, The assessment of anxiety states by rating, British Journal of Medical Psychology, 32, 50, 10.1111/j.2044-8341.1959.tb00467.x · DOI · Paper page
  9. Hunot, 2006, Psychological therapies for generalised anxiety disorder [Psychotherapy for generalized anxiety disorder], Cochrane Database of Systematic Reviews, 10.1002/14651858.CD001848.pub3 · DOI · Paper page
  10. Jadad, 1996, Assessing the quality of reports of randomised clinical trials: is blinding necessary?, Controlled Clinical Trials, 17, 1, 10.1016/0197-2456(95)00134-4 · DOI · Paper page
  11. Kessler, 1994, Lifetime and 12 month prevalence of DSM III R psychiatric disorders in the United States, Archives of General Psychiatry, 51, 8, 10.1001/archpsyc.1994.03950010008002 · DOI · Paper page
  12. Newall, 1996, Herbal medicines: a guide for health care professionals
  13. Olin, 1989, Passion Flower monograph
  14. Pitter, 2002, Kava extract for treating anxiety, Cochrane Database of Systematic Reviews
  15. Priest, 1988, Benzodiazepines and dependence: A college statement, Bulletin of the Royal College of Psychiatrists, 12, 107, 10.1192/pb.12.3.107 · DOI
  16. Rickels, 1993, Antidepressants for the treatment of generalized anxiety disorder: aplacebo controlled comparison of imipramine, trazodone and diazepam, Arch Gen Psychiatry, 50, 884, 10.1001/archpsyc.1993.01820230054005 · DOI · Paper page
  17. Schulz, 1995, Empirical evidence of bias: dimension of methodological quality associated with estimates of treatment effects in controlled trials, JAMA, 273, 408, 10.1001/jama.1995.03520290060030 · DOI
  18. Taylor, 1978, Relaxation training and related techniques In: Behavioral modifications: principles and clinical applications
  19. Taylor, 1988, The nature and the treatment of anxiety disorders
  20. Walley, 1994, Management of common anxiety disorders, American Family Physician, 50, 1745

Cited by

See all 78

Metadata

Authors
Miyasaka, L. S., Atallah, Á. N., & Soares, B.
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2007-01-24
Volume
2010
Issue
1
Pages
CD004518-CD004518
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
OpenAlex
W1586845255
Cited by
78
References
4
FWCI
17.46
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Passiflora for anxiety disorder. https://app.cochat.ai/papers/10.1002/14651858.cd004518.pub2
The paper
Miyasaka, L. S., Atallah, Á. N., & Soares, B. (2007). Passiflora for anxiety disorder. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd004518.pub2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.